First American Bank raised its stake in Eli Lilly and Co (NYSE:LLY) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,008 shares of the company’s stock after acquiring an additional 2,164 shares during the quarter. First American Bank’s holdings in Eli Lilly and were worth $5,828,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. First Financial Corp IN increased its stake in shares of Eli Lilly and by 0.8% in the second quarter. First Financial Corp IN now owns 17,245 shares of the company’s stock valued at $1,420,000 after buying an additional 136 shares during the period. Iowa State Bank acquired a new position in shares of Eli Lilly and in the second quarter valued at approximately $207,000. Buffington Mohr McNeal acquired a new position in shares of Eli Lilly and in the second quarter valued at approximately $374,000. Liberty Capital Management Inc. increased its stake in shares of Eli Lilly and by 283.3% in the second quarter. Liberty Capital Management Inc. now owns 2,300 shares of the company’s stock valued at $189,000 after buying an additional 1,700 shares during the period. Finally, Town & Country Bank & Trust CO dba First Bankers Trust CO increased its stake in shares of Eli Lilly and by 2.8% in the second quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 45,182 shares of the company’s stock valued at $3,718,000 after buying an additional 1,247 shares during the period. 76.49% of the stock is owned by hedge funds and other institutional investors.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 251,088 shares of company stock valued at $22,041,236. Insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE LLY) traded down $0.05 during mid-day trading on Tuesday, hitting $85.44. 6,374,000 shares of the stock traded hands, compared to its average volume of 3,591,457. The firm has a market cap of $93,360.00, a P/E ratio of 40.69, a price-to-earnings-growth ratio of 1.67 and a beta of 0.35. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 EPS. equities analysts expect that Eli Lilly and Co will post 4.22 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.63%. Eli Lilly and’s dividend payout ratio (DPR) is 99.05%.
LLY has been the subject of several recent research reports. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Thursday, October 26th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Finally, Cowen reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday, October 4th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $92.41.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.truebluetribune.com/2018/01/23/first-american-bank-boosts-stake-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.